CHARM Therapeutics

Executive Summary

CHARM Therapeutics is a US-UK biotechnology company pioneering AI-driven 3D deep learning for small molecule drug discovery in oncology. Its proprietary DragonFold platform predicts protein-ligand structures, enabling drug design against targets that lack experimental structures—a critical advantage for challenging oncology targets. The company has raised $80 million in funding and is building a preclinical pipeline of targeted cancer therapies. By integrating AI with structural biology, CHARM aims to accelerate the identification of novel drug candidates and expand the druggable proteome. While still in the preclinical stage, the company's technology has the potential to address high unmet needs in oncology, and its progress will be closely watched by investors seeking AI-enabled drug discovery platforms.

Upcoming Catalysts (preview)

• Q3 2026Lead optimization data for lead program50% success
• Q4 2026Series B financing or strategic partnership70% success
• H1 2027IND-enabling studies initiation40% success